Employees: 224
Size Alumis (ALMS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $569M, the 2579th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.39 on 18 Nov 2026.
Performance Over six months the shares fell 80.1%, against -20.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 67.3% over the last twelve months (peer median +4.6%); the operating margin is -5,374.5% (peer median 6.6%).
Valuation It trades at 23.9× enterprise value to sales against a peer median of 2.6× (3rd most expensive of 18).
Short interest Short interest is 8.5% of the free float (30 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $7.24M | $24.1M | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $3.74M | $20.6M | -$3.15M | -$1.28M | -$250,000 |
| EBITDA | -$386M | -$424M | -$298M | -$157M | -$114M |
| Net income | -$423M | -$243M | -$294M | -$155M | -$112M |
| Free cash flow | -$321M | -$370M | -$257M | -$134M | -$110M |
| Capital expenditure | $865,000 | $653,000 | $1.73M | $4.50M | $2.41M |
| Total debt | $35.3M | $36.9M | $30.7M | $32.6M | $1.78M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -34.4% | -11.1% | 2nd lowest of 21 |
| 6-month return | -80.1% | -20.1% | lowest of 21 |
| Distance from 52-week high | -86.0% | -42.1% | lowest of 21 |
| Revenue growth (TTM) | -67.3% | +4.6% | 3rd lowest of 19 |
| Operating margin | -5,374.5% | 6.6% | lowest of 18 |
| EV / Sales | 23.9× | 2.6× | 3rd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |